Cargando…
Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged...
Autores principales: | Schwarz, T, Spaczynski, M, Kaufmann, A, Wysocki, J, Gałaj, A, Schulze, K, Suryakiran, P, Thomas, F, Descamps, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489326/ https://www.ncbi.nlm.nih.gov/pubmed/25208608 http://dx.doi.org/10.1111/1471-0528.13070 |
Ejemplares similares
-
Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017) -
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014) -
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study
por: Romanowski, Barbara, et al.
Publicado: (2014) -
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
por: Romanowski, Barbara, et al.
Publicado: (2015) -
Uterine artery embolization or myomectomy for women with uterine fibroids: Four-year follow-up of a randomised controlled trial
por: Daniels, Jane, et al.
Publicado: (2021)